


EFS-Web Receipt date: 03/30/2006

EFS-Web Receipt date: 03/30/2006



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number	10/540,369
		Filing Date	June 23, 2005
		First Named Inventor	Z. Terashita
		Art Unit	1646--
		Examiner Name	tba--STOCKTON
Sheet	1- 3	of	1- 3
		Attorney Docket Number	3150 US0P

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		ORTLEPP, J., et al., "Angiotensin II Receptor Antagonism and ACE Inhibition Ameliorate Hyperinsulinemia and Obesity in a Murine Model of Polygenic Obesity", <u>Journal of the American College of Cardiology</u> , (2002), Vol. 39, No. 5, Supplement A, page 232A	
		NODA, M., et al., "Involvement of Angiotensin II in Progression of Renal Injury in Rats with Genetic Non-Insulin-Dependent Diabetes Mellitus (Wistar Fatty Rats)", <u>Japan J. Pharmacol.</u> , (2001), Vol. 85, pages 416-422	

Examiner Signature	/Laura L. Stockton/	Date Considered	04/10/2008
--------------------	---------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /LLS/